Hepatocyte growth factor sensitizes brain tumors to c-Met kinase inhibition.
CONCLUSIONS: These findings allow the identification of a subset of patients that will be responsive to c-MET inhibition, and propose ligand pre-treatment as a potential new strategy for improving the anti-cancer efficacy of RTK inhibitors.
PMID: 23386689 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
View Source
